Description: Pfizer on Tuesday raised the full-year sales forecast for its Covid-19 vaccine by 7.5% to $36 billion, as it signs deals with countries for booster doses and receives clearances for using its shots in children.
Source: CNBC.com – video report
Date: Nov 02, 2021
?Questions for discussion:
- What can affect Pfizer’s future vaccine revenues?
- Do you think the stock is a good buy or too great a risk because of these factors?
Leave a Reply
You must be logged in to post a comment.